{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-106646","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.769756+00:00","generated_at":"2026-05-29T05:37:23.566952+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review","bullets":["Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.","Decision follows data monitoring committee evaluation of full Reliance II dataset.","Will continue advancing Phase 1 study of REL-P11, a metabolic disease investigational agent.","Commenced process to explore strategic alternatives including sale, merger, or asset acquisition.","Engaging financial advisor; no timetable set for completion of strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-106646","json":"https://secwatch.observer/filing/0001213900-24-106646.json","markdown":"https://secwatch.observer/filing/0001213900-24-106646.md","text":"https://secwatch.observer/filing/0001213900-24-106646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/0001213900-24-106646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/ea0224026-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:37:23.566952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}